{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T01:15:03Z","timestamp":1768094103499,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Biosplice Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40744-023-00604-7","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T11:01:50Z","timestamp":1698663710000},"page":"1741-1752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7\u00a0Days: An Open-Label, Randomized, Parallel-Arm Study"],"prefix":"10.1007","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct04598542","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mark S.","family":"Fineman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy E.","family":"McAlindon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Lattermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Swearingen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor A.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail","family":"Simsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeyanesh R. S.","family":"Tambiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"604_CR1","doi-asserted-by":"publisher","first-page":"9332","DOI":"10.1073\/pnas.1703856114","volume":"114","author":"IJ Wallace","year":"2017","unstructured":"Wallace IJ, Worthington S, Felson DT, et al. Knee osteoarthritis has doubled in prevalence since the mid-20th century. Proc Natl Acad Sci U S A. 2017;114:9332\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"604_CR2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.joca.2022.11.005","volume":"31","author":"MJ Richard","year":"2023","unstructured":"Richard MJ, Driban JB, McAlindon TE. Pharmaceutical treatment of osteoarthritis. Osteoarthr Cartil. 2023;31:458\u201366.","journal-title":"Osteoarthr Cartil"},{"key":"604_CR3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.joca.2021.02.004","volume":"29","author":"Y Yazici","year":"2021","unstructured":"Yazici Y, McAlindon TE, Gibofsky A, et al. A phase\u00a02b randomized trial of lorecivivint, a novel intra-articular CLK2\/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthr Cartil. 2021;29:654\u201366.","journal-title":"Osteoarthr Cartil"},{"key":"604_CR4","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.joca.2017.07.006","volume":"25","author":"Y Yazici","year":"2017","unstructured":"Yazici Y, McAlindon TE, Fleischmann R, et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase\u00a01 study. Osteoarthr Cartil. 2017;25:1598\u2013606.","journal-title":"Osteoarthr Cartil"},{"key":"604_CR5","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). Federal Register Vol. 83, No. 41, p. 8882\u20133; 2016. https:\/\/www.ich.org\/. Accessed 15 June 2023."},{"key":"604_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.joca.2017.10.003","volume":"26","author":"VB Kraus","year":"2018","unstructured":"Kraus VB, Conaghan PG, Aazami HA, et al. Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). Osteoarthr Cartil. 2018;26:34\u201342.","journal-title":"Osteoarthr Cartil"},{"key":"604_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.joca.2017.08.015","volume":"26","author":"V Deshmukh","year":"2018","unstructured":"Deshmukh V, Hu H, Barroga C, et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthr Cartil. 2018;26:18\u201327.","journal-title":"Osteoarthr Cartil"},{"key":"604_CR8","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/rheumatology\/keaa808","volume":"60","author":"S Ayub","year":"2021","unstructured":"Ayub S, Kaur J, Hui M, et al. Efficacy and safety of multiple intra-articular corticosteroid injections for osteoarthritis\u2014a systematic review and meta-analysis of randomized controlled trials and observational studies. Rheumatology (Bulgaria). 2021;60:1629\u201339.","journal-title":"Rheumatology (Bulgaria)"},{"key":"604_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/pm\/pnx303","volume":"19","author":"J Patel","year":"2018","unstructured":"Patel J, Schneider BJ, Smith CC. Fact finders for patient safety: intra-articular corticosteroid injections and hyperglycemia. Pain Med. 2018;19:1091\u20132.","journal-title":"Pain Med"},{"key":"604_CR10","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/art.41315","volume":"72","author":"Y Yazici","year":"2020","unstructured":"Yazici Y, McAlindon TE, Gibofsky A, et al. Lorecivivint, a novel intraarticular CDC-like kinase\u00a02 and dual-specificity tyrosine phosphorylation-regulated kinase\u00a01A inhibitor and Wnt pathway modulator for the treatment of knee osteoarthritis: a phase II randomized trial. Arthritis Rheumatol. 2020;72:1694\u2013706.","journal-title":"Arthritis Rheumatol"},{"key":"604_CR11","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3390\/pharmaceutics13122166","volume":"13","author":"Y Cao","year":"2021","unstructured":"Cao Y, Ma Y, Tao Y, Lin W, Wang P. Intra-articular drug delivery for osteoarthritis treatment. Pharmaceutics. 2021;13:2166.","journal-title":"Pharmaceutics"},{"key":"604_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.actbio.2019.03.010","volume":"93","author":"S Brown","year":"2019","unstructured":"Brown S, Kumar S, Sharma B. Intra-articular targeting of nanomaterials for the treatment of osteoarthritis. Acta Biomater. 2019;93:239\u201357.","journal-title":"Acta Biomater"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00604-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00604-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00604-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:42:57Z","timestamp":1700152977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00604-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00604-7","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"23 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark Fineman, PhD, Christopher J. Swearingen, PhD, Sarah Kennedy, PhD, Victor A. Lopez, MS, Ismail Simsek, MD, Jeyanesh R.S.\u00a0Tambiah, MD, and Yusuf Yazici, MD are current or past employees and shareholders of Biosplice Therapeutics. Timothy McAlindon, MD, MPH, is a consultant and investigator for Biosplice Therapeutics, a consultant to Kolon TissueGene, Organogenesis, Remedium-Bio, Medipost, ChemoCentryx, and Xalud, with business interest in Ambulomics, Inc. Christian Lattermann, MD is a consultant for Biopslice Therapeutics and a consultant to Organogenesis, Aesculap and Vericel, Scientifc Board Member of On-Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The research within this clinical trial was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice Guidelines, and all applicable regulations. The trial was conducted under institutional review board approval by Advarra (Columbia, MD) (approval date 7\u00a0October 2020, approval reference\u00a0MOD00817729). All participants provided written informed consent prior to engaging in any study-related procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}